We have a drug that could transform HIV prevention. So why can’t millions get it? A twice-yearly injection could revolutionise HIV prevention. But who gets access raises bigger questions about public money, pharmaceutical power, drug prices and shrinking global health funding. Al Jazeera’s Mikail Malik looks at the fight over access.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。